Idiopathic parkinson disease. Effect of levodopa on apparent diffusion coefficient value of the brain

Academic Radiology

Volumn 18, Issue 1, 2011, Pages 70-73

  Abdel Razek, Ahmed Abdel Khalek ^a   Elmongy, Azza ^a   Hazem, Maha ^a   Zakareyia, Shirin ^a   Gabr, Wael ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Diffusion; MR imaging; Parkinson's

Indexed keywords

LEVODOPA;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG EFFECT; ECHO PLANAR IMAGING; FEMALE; HUMAN; IDIOPATHIC DISEASE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SENSITIVITY AND SPECIFICITY;

AGED; ANTIPARKINSON AGENTS; BRAIN; BRAIN MAPPING; DIFFUSION MAGNETIC RESONANCE IMAGING; ECHO-PLANAR IMAGING; FEMALE; HUMANS; LEVODOPA; MALE; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 78649967020     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2010.08.023     Document Type: Article

References (27)

1. Tolosa E., Wenning G., Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006, 5:75-86.
2. Marras C., Lang A. Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology 2008, 70:1996-2003.
3. Clarke C.E. Medical management of Parkinson's disease. J Neurol Neurosurg Psychiatr 2002, 72:122-127.
4. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 2005, 22:731-740.
5. Torstenson R., Hartvig P., Lngstrom B., et al. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann Neurol 1997, 41:334-340.
6. Muller T., Hefter H., Hueber R., et al. Is levodopa toxic?. J Neurol 2004, 251(Suppl 6):VI/44-VI/46.
7. Antonini A., Schwarz J., Oertel W., et al. [11C] raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994, 44:1325-1329.
8. Simoes-Ribeiro F., Mendes-Ribeiro J., Soares R., et al. Proton magnetic resonance spectroscopy findings in Parkinson's disease: drug-naive vs levodopa-treated dyskinetic vs levodopa-treated non-dyskinetic patients. Mov Disord 1998, 13:173-174.
9. Salgado-Pineda P., Delaveau P., Falcon C., et al. Brain T1 intensity changes after levodopa administration in healthy subjects: a voxel-based morphometry study. Br J Clin Pharmacol 2006, 62:546-551.
10. Brusa L., Bassi A., Pierantozzi M., et al. Perfusion-weighted dynamic susceptibility (DSC) MRI: basal ganglia hemodynamic changes after apomorphine in Parkinson's disease. Neurol Sci 2002, 23(Suppl 2):S61-S62.
11. Kraft E., Loichinger W., Diepers M., et al. Levodopa-induced striatal activation in Parkinson's disease: A functional MRI study. Parkinsonism Related Disord 2009, 15:558-563.
12. Degirmenci B., Yaman M., Haktanir A., et al. The effects of levodopa use on diffusion coefficients in various brain regions in Parkinson's disease. Neurosci Lett 2007, 416:294-298.
13. Hughes A., Daniel S., Kilford L., et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
14. Seppi K., Poewe W. Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin North Am 2010, 20:29-55.
15. Sitburana O., Ondo W. Brain magnetic resonance imaging (MRI) in parkinsonian disorders. Parkinsonism Related Disord 2009, 15:165-174.
16. Brooks D. Assessment of Parkinson's disease with imaging. Parkinsonism Related Disord 2007, 13:S268-S275.
17. Menke R., Scholz J., Miller K., et al. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. NeuroImage 2009, 47:435-441.
18. Vaillancourt D.E., Spraker M.B., Prodoehl J., et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009, 72:1378-1384.
19. Gattellaro G., Minati L., Grisoli M., et al. White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study. AJNR Am J Neuroradiol 2009, 30:1222-1226.
20. Tessa C., Giannelli M., Della N.R., et al. A whole-brain analysis in de novo Parkinson disease. AJNR Am J Neuroradiol 2008, 29:674-680.
21. Kendi A.T., Lehericy S., Luciana M., et al. Altered diffusion in the frontal lobe in Parkinson disease. AJNR Am J Neuroradiol 2008, 29:501-505.
22. Chan L.L., Rumpel H., Yap K., et al. Case control study of diffusion tensor imaging in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007, 78:1383-1386.
23. Rizzo G., Martinelli P., Manners D., et al. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Brain 2008, 131:2690-2700.
24. Paviour D., Thornton J., Lees A., et al. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple system atrophy from progressive supranuclear palsy. Mov Disord 2007, 22:68-74.
25. Ito M., Watanabe H., Kawai Y., et al. Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. J Neurol Neurosurg Psychiatry 2007, 78:722-728.
26. Blain C., Barker G., Jarosz J., et al. Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI. Neurology 2006, 67:2199-2205.
27. Nicoletti G., Lodi R., Condino F., et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006, 129:2679-2687.